The biological activities of butyrylcholinesterase inhibitors.
Biomed Pharmacother
; 146: 112556, 2022 Feb.
Article
em En
| MEDLINE
| ID: mdl-34953393
ABSTRACT
Acetylcholinesterase (AChE) inhibitor is the first choice for the treatment of Alzheimer's disease (AD), but it has some defects, such as dose limitation and unsatisfactory long-term treatment effect. Recent studies have shown that butyrylcholinesterase (BuChE) inhibitors or double acetyl and butyryl cholinesterase inhibitors have better curative effects on AD, and the side effects are lower than those of specific AChE inhibitors. Dual target cholinesterase inhibitors have become a new hotspot in the research of anti-AD drugs. Herein, the synthesis and bioactivities of BuChE inhibitors were reviewed.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Butirilcolinesterase
/
Inibidores da Colinesterase
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article